Drug Trial Radar · NCT07940179
Access Study Assessing the Safety of Prostate-specific Membrane Antigen Radioligands for Positron Emission Tomography
Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
5,000
Planned (sponsor's estimate)
Start
Nov 4, 2021
Primary completion
Dec 31, 2031
Study completion Dec 31, 2032
Sponsor
- Lead sponsor
- Jean-Mathieu BeauregardAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Nov 16, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Diagnostic
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to make non-approved PSMA radioligands available at CHU de Québec - Université Laval, while assessing their safety. Our hypothesis is that all the PSMA PET radioligand are safe, with a very low incidence of adverse events (AEs). The potential clinical impact of PSMA-PET will be explored in our clinical setting.
Conditions
- Prostate Cancer
- Other Cancers
Interventions
PET PSMA tracerDrug
Administration of a PSMA tracer for PET
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of Participants with PSMA PET radiopharmaceuticals-Related Adverse Events as Assessed by CTCAE v5.0 .Time frame: up to 1 week
Locations
1 site in 1 country. Site status is shown where the registry gives one.
CHU de Quebec-Université Laval
Québec, Quebec, Canada · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.